Repurposing potential of ketamine: Opportunities and challenges
Indian Journal of Psychological Medicine, 2020 Ketamine is a noncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor which also interacts with various other receptors that account for its myriad actions.
C S Gautam +4 more
doaj +1 more source
ESKETAMINE NASAL SPRAY FOR DEPRESSIVE PATIENTS
, 2023 Abstract: Ketamine can promptly reduce suicidality and relieve other serious symptoms of depression. Esketamine (Spravato), FDA approved is usually given as a nasal spray. It operates under “S” molecule. Ketamine can be administered intranasally (spray into the nose) for treating resistant mood disorders like depression.
openaire +1 more source
Safety and Efficacy of Adjunctive Esketamine vs. MAOIs in TRD in Adults [PDF]
, 2023 Background: Depression affects millions globally - Treatment-resistant depression (TRD) is defined as failure to respond to two antidepressant trials of adequate dose and duration Traditional Treatment for TRD: Switching or adding medications atypical ...
Guinan, Riley
core +1 more source
The Ketamine Side Effect Tool (KSET):A comprehensive measurement-based safety tool for ketamine treatment in psychiatry [PDF]
, 2022 Objectives: On a background of the rapidly expanding clinical use of ketamine and esketamine for treatment of depression and other conditions, we examined safety monitoring, seeking to identify knowledge gaps relevant to clinical practice.
Bayes, Adam +17 more
core +3 more sources
Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review [PDF]
, 2021 Esketamine (ESK) has been approved as a rapid-acting intranasal treatment for treatment-resistant depression (TRD). Although existing studies have investigated the efficacy of ESK in the 4-week induction phase, our knowledge about long-term ESK efficacy ...
Buoli M +8 more
core +1 more source
Q: Is ketamine effective and safe for treatment-resistant depression? [PDF]
, 2021 Evidence-based answer: Maybe, but it’s too soon to tell. There is limited evidence that ketamine by itself is effective in the very short term. Single-dose intravenous (IV) ketamine is more likely than placebo (odds ratio = 11-13) to produce improvement (
Jenkinson, Mat +4 more
core +1 more source
Are we repeating mistakes of the past? A review of the evidence for esketamine [PDF]
, 2020 Esketamine has been licensed for 'treatment-resistant depression' in the USA, UK and Europe. Licensing trials did not establish efficacy: two trials were negative, one showed a statistically significant but clinically uncertain effect, and a flawed ...
Horowitz, MA, Moncrieff, J
core
European PsychiatryIntroduction Esketamine intranasal spray has been approved in both the USA and EU as a novel treatment in patients with treatment-resistant major depression (TRD) and for the management of acute depressive emergencies during the course of major ...
E. Kavakbasi +4 more
doaj +1 more source
The Resistant Depression Response to Esketamine Assessing Metabolomics (ReDREAM) Project-Untargeted Metabolomics to Identify Biomarkers of Treatment Response to Intranasal Esketamine in Individuals with Treatment-Resistant Depression: A Study Protocol [PDF]
Objective: Treatment-resistant depression (TRD) affects around 20-30% of people with major depressive disorder. In 2019, esketamine nasal spray was approved for TRD by both the US Food and Drug Administration and the European Medicines Agency.
Albert, Umberto +9 more
core +1 more source
EFFICACY OF INTRANASAL ESKETAMINE AS A NOVEL RAPID ANTIDEPRESSANT IN ADULTS WITH TREATMENT- RESISTANT DEPRESSION [PDF]
, 2023 Major depressive disorder (MDD), the leading cause of disability worldwide is a common and disabling mental health disorder associated with high suicide-related morbidity and mortality rates.
Annalicia Setiawan, Aurielle +4 more
core +1 more source